A5013308464- Polyomavirus and related diseases
- Bacteriophages and microbial interactions
- Health Systems, Economic Evaluations, Quality of Life
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Full-Duplex Wireless Communications
- Microwave Engineering and Waveguides
- Biosimilars and Bioanalytical Methods
- RNA Research and Splicing
- RNA and protein synthesis mechanisms
- Economic and Financial Impacts of Cancer
- Colorectal and Anal Carcinomas
- Pharmaceutical studies and practices
- Statistical Methods in Clinical Trials
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
- Antenna Design and Analysis
- RNA modifications and cancer
- Plant Virus Research Studies
- Metastasis and carcinoma case studies
BresMed
2017-2022
The Alfred Hospital
1936
Metastatic Merkel cell carcinoma (mMCC) is a rare and aggressive skin cancer. Until recently, there were no licensed treatment options for patients with mMCC, prognosis was poor. A cost-effectiveness analysis conducted avelumab, newly available option versus standard care (SC), from UK National Health Service perspective.A partitioned survival model developed to assess the lifetime costs effects of avelumab SC. Data JAVELIN 200 trial (NCT02155647) used inform estimates quality-adjusted...
Abstract Background Due to limited duration of follow up in clinical trials cancer treatments, estimates lifetime survival benefits are typically derived using statistical extrapolation methods. To justify the method used, a range approaches have been proposed including goodness-of-fit tests and comparing against previous data cut (i.e. interim collected). In this study, we extend these by presenting extrapolations fitted four pre-planned cuts from JAVELIN Merkel 200 (JM200) trial. By...
e21620 Background: Data from the JAVELIN Merkel 200 (JM 200) trial of avelumab in mMCC with a minimum follow-up 18 mo for 88 pts who had received prior chemotherapy demonstrated robust survival estimates. Available data treatment-naive are less mature due to partial enrolment (Mar 24, 2017 cut: 6 wk min follow-up, 39 enrolled). To enable treatment reimbursement decisions, health technology assessment agencies require long-term data. provide this, current analysis used novel statistical...